Terns Pharma Stock (NASDAQ:TERN), Trade Ideas

Terns Pharma

Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AFRM

AMCX

BILL

BTAI

BTTR

CENT

CLSK

CNTA

DOOR

EGAN

EMKR

EXPE

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

IBEX

IGMS

ILAG

ILMN

Intelligent Bio Solutions Inc. - Common Stock

INBS

IREN

LTRX

MLGO

MTRX

NGVC

NSTG

OCUL

PINS

PLCE

RNLX

SHCO

STRM

SUNW

SYBX

TCBP

TERN

TTWO

VIRC

ZJYL

Shares of  Take-Two Interactive Software, Inc.  (NASDAQ: TTWO) fell sharply during Friday’s session following third-quarter results.

Why Take-Two Interactive Software Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Short Ideas

Pre-Market Outlook

EYPT

OMER

As of Dec. 5, 2023, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Top 5 Health Care Stocks That Are Ticking Portfolio Bombs

Alterity Therapeutics Limited - American Depositary Shares

ATHE

BETS

BIOL

BYND

CLIN

CUEN

CUTR

CVNA

DUNE

FOXO

GSIW

LSDI

MARA

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

MINM

MMAT

MNSO

MRAI

NEGG

NEXI

NLSP

NMRA

PLTR

REBN

RILY

SAIC

SANA

SLNH

SPCE

SPOT

SSNT

UCAR

VIEW

VVOS

WULF

SOAR

Shares of U Power Limited  (NASDAQ: UCAR) shares moved lower during Monday’s session after the company announced pricing of registered follow-on offering of 10 million units at a purchase price of $1.20 per unit.

Why U Power Shares Are Trading Lower By Around 54%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Terns Pharmaceuticals, Inc. - Common Stock

Terns Pharmaceuticals Inc

Tern PLC

Terna Energy SA

TERNA ENERGY SA UNSP/ADR by Terna Energy SA

TRASMISSIONE ELECTR ORD by Terna Rete Elettrica Nazionale SPA

Terna SpA

TERNA RETE ELETTRICA ADR by Terna Rete Elettrica Nazionale SPA

TERNIUM ARGENTINA S A by TERNIUM ARGENTINA S A

Ternium Argentina SA

Ternium S.A. Ternium S.A. American Depositary Shares (each representing ten shares, USD1.00 par value)

Ternium SA

Ternoa

Goldman Sachs analyst Noah Poponak maintains CAE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAE#NYSE">CAE</a>) with a Buy and raises the price target from $25 to $29.

Price Target

Analyst Ratings

Goldman Sachs Maintains Buy on CAE, Raises Price Target to $29

Benchmark analyst Christopher Kuhn maintains XPO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) with a Buy and raises the price target from $125 to $140.

Benchmark Maintains Buy on XPO, Raises Price Target to $140

Goldman Sachs analyst Gavin Parsons maintains CACI International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CACI#NYSE">CACI</a>) with a Neutral and raises the price target from $379 to $425.

CACI

Goldman Sachs Maintains Neutral on CACI International, Raises Price Target to $425

In an exclusive interview with Benzinga, Michael Sayers, CFA and vice president and portfolio manager at Rockland Trust, shared valuable insights into <a href="http://benzinga.com/topic/economy">today&#8217;s investment opportunities.</a> 
Below, we explore the key questions and Sayers&#8217; insightful responses:
<h2 class="wp-block-heading">How The CHIPS Act, IRA Act &amp; Infrastructure Act Create Investment Opportunities</h2>
When asked about the anticipated influence of recent legislative developments like the CHIPS Act, IRA Act, and Infrastructure Act on investment opportunities, Sayers provided a comprehensive overview. 
Regarding the potential effects of the CHIPS Act on technology investments and the semiconductor industry, Sayers pointed out the significant earmarked funds for semiconductors. 
He highlighted the substantial infrastructure-related spending authorized by these acts, totaling approximately $1 trillion over the next decade.
<h2 class="wp-block-heading">A Significant Amount Of Money Still On The Table</h2>
Some quick back-of the napkin math by Sayers went as follows;
&#8220;Infrastructure-related spending across the Inflation Reduction Act (IRA), Infrastructure, and CHIPS acts totals ~$1 Trillion over a period of 10 years ending in 2031. About $650 billion has been authorized/committed so far.&#8221;
<ul>
<li>About $250 billion has been allocation to semiconductors.</li>
</ul>
This should benefit investments into the iShares Semiconductor ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NYSE">SOXX</a>) which provides exposure to the semiconductor equity sector in the U.S.
<ul>
<li>Another $250 billion to clean energy and power.</li>
</ul>
The iShares Global Clean Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ICLN#NYSE">ICLN</a>), along with the Invesco Solar ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAN#NYSE">TAN</a>) are among the two most popular ETFs that should benefit from this allocation.
<ul>
<li>$150 billion has been allocated for EV and EV batteries.</li>
</ul>
Investors in the Global X Autonomous &amp; Electric Vehicles ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIV#NASDAQ">DRIV</a>), the iShares Self-Driving EV and Tech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDRV#NYSE">IDRV</a>) and the KraneShares Electric Vehicles and Future Mobility Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KARS#NYSE">KARS</a>) which invest in stocks of electric vehicle manufacturers, should see this benefit trickling down to them.
&#8220;That leaves a significant amount of money still on the table, particularly under the IRA &amp; CHIPS acts,&#8221; Sayer said pointing to $350 billion remaining from the total $1 trillion allocation.
<h2 class="wp-block-heading">Multi-Year Runway Of Annualized Double-Digit Growth Ahead</h2>
Backed by the $350 billion remaining, Sayers emphasized, &#8220;There is a multi-year runway of annualized double-digit growth in infrastructure-related construction &amp; manufacturing spending ahead of us through the end of the decade.&#8221;
Rockland Trust allocates to the Russell Global Infrastructure Fund (RGISX) to take advantage of this positive outlook but also to provide diversification to the high-quality stock &amp; bond portfolios that the firm manages for its clients
Investment Opportunities: Building upon Sayer&#8217;s insights into the potential growth in infrastructure and manufacturing sectors, let&#8217;s explore capital market instruments that investors could utilize to partake in this anticipated growth. Various Exchange-Traded Funds (ETFs) present attractive options for investors seeking exposure to these sectors.
ETFs for Infrastructure and Manufacturing Sectors: Infrastructure ETFs such as PAVE, IGF, and IFRA, as well as Manufacturing/Industrials ETFs like XLI and ITA, offer exposure to sectors poised for growth amid these legislative developments.
Let&#8217;s first look at the top infrastructure ETFs
These ETFs provide investors with diversified portfolios of companies operating in infrastructure development, manufacturing, and related industries, aligning with the anticipated growth trajectories highlighted by Sayers.
Some popular Infrastructure ETFs include:
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Symbol</td>
<td>ETF</td>
<td> Total Assets ($MM)</td>
<td> YTD% (as of April 15)</td>
</tr>
<tr>
<td>PAVE</td>
<td>Global X US Infrastructure Development ETF</td>
<td>$7,514.84 </td>
<td>+11.32%</td>
</tr>
<tr>
<td>IGF</td>
<td>iShares Global Infrastructure ETF</td>
<td>$3,503.42</td>
<td>-1.49%</td>
</tr>
<tr>
<td>IFRA</td>
<td>iShares U.S. Infrastructure ETF</td>
<td>$2,320.23</td>
<td>4.71%</td>
</tr>
<tr>
<td>NFRA</td>
<td>FlexShares STOXX Global Broad Infrastructure Index Fund</td>
<td>$2,215.70</td>
<td>-2.04%</td>
</tr>
</tbody>
</table>
</figure>
Now let&#8217;s look at the top Manufacturing/Industrial ETFs
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td> Symbol </td>
<td>ETF</td>
<td>Total Assets ($MM)</td>
<td>YTD% (as of April 15)</td>
</tr>
<tr>
<td>XLI</td>
<td>XLI Industrial Select Sector SPDR Fund</td>
<td>$18,253,700</td>
<td>8.15%</td>
</tr>
<tr>
<td>ITA</td>
<td>ITA iShares U.S. Aerospace &amp; Defense ETF</td>
<td>$5,998,910</td>
<td>1.09%</td>
</tr>
<tr>
<td>VIS</td>
<td>VIS Vanguard Industrials ETF</td>
<td>$5,328,240</td>
<td>7.99%</td>
</tr>
<tr>
<td>PPA</td>
<td>PPA Invesco Aerospace &amp; Defense ETF</td>
<td>$3,012,080</td>
<td>7.63%</td>
</tr>
<tr>
<td>FXR</td>
<td>FXR First Trust Industrials/Producer Durables AlphaDEX Fund</td>
<td>$1,942,100 </td>
<td>8.12%</td>
</tr>
</tbody>
</table>
</figure>
Investors can strategically navigate legislative developments and capitalize on emerging growth sectors by leveraging ETFs tailored to infrastructure and manufacturing industries. 
With the guidance of financial professionals and thorough research, investors can position themselves to benefit from the evolving economic landscape.
Now Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38265826/high-interest-rates-could-cause-more-things-to-break-in-us-economy-by-2025-warns-st">High-Interest Rates Could Cause &#8216;More Things To Break&#8217; In US Economy By 2025, Warns Strategist </a>
Image generated using artificial intelligence via Midjourney.

Government

Regulations

Sector ETFs

Specialty ETFs

Exclusives

Interview

ETFs

DRIV

First Trust Industrials/Producer Durables AlphaDEX Fund

iShares S&P Global Clean Energy Index Fund

ICLN

IDRV

IFRA

iShares S&P Global Infrastructure Index Fund

iShares Dow Jones US Aerospace & Defense Index Fund

KARS

NFRA

PAVE

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

EXCLUSIVE: Expert Predicts 'Double-Digit Growth' In 2 Sectors Thanks To Major Federal Investments

BNED to Receive $95 Million of New Capital Through $50 Million Equity Investment and $45 Million Fully Backstopped Equity Rights Offering Led by Immersion Corporation
Eliminates Approximately $34 Million of Debt Through Equitization of Second Lien Term Loan, Reflecting Strong Support of Key Strategic Partners
Secures Commitment to Refinance Four-Year Asset Backed Loan Facility to Provide Greater Financial and Operational Flexibility
Barnes &amp; Noble Education, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BNED#NYSE">BNED</a>) ("BNED" or the "Company"), a leading solutions provider for the education industry, today announced that it has entered into a definitive agreement with Immersion Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMMR#NASDAQ">IMMR</a>) ("Immersion"), and certain of the Company's existing shareholders and strategic partners, on the terms of new equity and refinancing transactions that will significantly strengthen BNED's long-term financial position. The proposed transactions, which are subject to shareholder approval and other closing conditions, will enable the Company to substantially deleverage its balance sheet, continue to strategically invest in innovation, and operate from a position of strength.
Upon close, which is expected in June 2024:
<ul>
<li>BNED will receive gross proceeds of $95 million of new equity capital through a $50 million new equity investment (the "Private Investment") led by Immersion and a $45 million fully backstopped equity rights offering (the "Rights Offering"); the transactions are expected to infuse approximately $75 million of net cash proceeds after transaction costs;</li>
<li>The Company's existing second lien lenders, affiliates of Fanatics, Lids, and VitalSource Technologies ("VitalSource") (collectively, the "Second Lien Lenders"), will convert approximately $34 million of outstanding principal and any accrued and unpaid interest into BNED Common Stock; and</li>
<li>The Company has received commitments to refinance its existing asset backed loan facility, pursuant to an agreement with its first lien holders, providing the Company with access to a $325 million facility (the "ABL Facility") maturing in 2028. The refinanced ABL Facility will meaningfully enhance BNED's financial flexibility and reduce its annual interest expense.</li>
</ul>
"Today's announcement marks a significant milestone in our strategic review process and, we believe, represents the best path forward for our shareholders, employees and the students, institutions, alumni, fans, and communities we serve," said Michael Huseby, Chief Executive Officer, BNED. "BNED is a critical part of the education ecosystem, and we are confident that this transaction will allow us to grow our business profitably as we enhance our market leading offerings and build on the strong momentum of First Day and our other key programs."
"With a stronger financial foundation, we will be well positioned to advance our industry leadership by continuing our focus on delivering innovative solutions, an unmatched merchandise assortment, and the best-in-class omnichannel customer experience for our valued school partners," said, Jonathan Shar, Executive Vice President, BNED Retail and President, Barnes and Noble College.

Contracts

BNED

IMMR

Barnes & Noble Education Announces Milestone Transactions To Significantly Strengthen Balance Sheet; To Receive $95M Of New Capital Through $50M Equity Investment And $45M Fully Backstopped Equity Rights Offering; Eliminates ~$34M Of Debt Through Equitization Of Second Lien Term Loan

WIIM

AUNA

Auna shares are trading higher after JP Morgan and Morgan Stanley initiated coverage on the stock with bullish ratings.

<ul>
<li>Acquisition capitalizes on TruHC's strategically built German cannabis platform, including:
<ul>
<li>EU-GMP processing and production license</li>
<li>GDP wholesale license for import / export</li>
<li>EU-GMP certified customizable modules with flexibility to incorporate various production / packaging processes and which enable license extension for future in country cultivation and supply to cannabis dispensaries</li>
<li>Narcotics license with EU-GMP certified storage</li>
<li>EU-GMP certified laboratory for instant cannabis analysis</li>
</ul>
</li>
<li>Transaction combines Flora's extensive global CPG and pharmaceutical distribution network with TruHC's deep global cannabis expertise, including an executive team with extensive experience building successful medical and recreational cannabis companies across Germany, Canada, and the United States.</li>
<li>Germany poised to become world's largest federally legal cannabis market with expected market potential of over $10 billion with federal legalization and the critical elimination of banking, financial, capital markets, and tax constraints faced by U.S. operators.</li>
</ul>

FLGC

Flora Growth Enters Into Definitive Agreement To Acquire TruHC In Exchange For 2,770,562 Flora Common Shares Valued At $6.4M

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bned.com&amp;esheet=53933160&amp;newsitemid=20240416021899&amp;lan=en-US&amp;anchor=Barnes+%26amp%3B+Noble+Education%2C+Inc.+%28NYSE%3A+BNED%29&amp;index=1&amp;md5=f6c1240132522a9bf4eb340d575dc31a">Barnes &amp; Noble Education, Inc. (NYSE:</a><a href="https://www.benzinga.com/stock/BNED#NYSE">BNED</a>), a leading solutions provider for the education industry, today announced that its Board of Directors has approved the adoption of a short-term stockholder rights plan and declared a dividend distribution of one preferred share purchase right on each outstanding share of the Company's common stock.
The rights will be exercisable only if a person or group acquires 10% or more of the Company's outstanding common stock, subject to certain exceptions. Each right will entitle stockholders to buy one one-thousandth of a share of a new series of junior participating preferred stock at an exercise price of $5.00.
If a person or group acquires 10% of the Company's outstanding common stock, each right will entitle its holder (other than such person or members of such group) to purchase for $5.00, a number of Company common shares having a market value of twice such price. In addition, at any time after a person or group acquires 10% of the Company's outstanding common stock, the Company's Board of Directors may exchange one share of the Company's common stock for each outstanding right (other than rights owned by such person or group, which would have become void).
Prior to the acquisition by a person or group of beneficial ownership of 10% of the Company's common stock, the rights are redeemable for one cent per right at the option of the Board of Directors.
Certain synthetic interests in securities created by derivative positions—whether or not such interests are considered to constitute beneficial ownership of the underlying common stock for reporting purposes under Regulation 13D of the Securities Exchange Act—are treated as beneficial ownership of the number of shares of the Company's common stock equivalent to the economic exposure created by the derivative position, to the extent actual shares of the Company's stock are directly or indirectly held by counterparties to the derivatives contracts.
The dividend distribution will be made on April 29, 2024, payable to stockholders on that date and is not taxable to stockholders. The rights will expire on January 31, 2025, unless the rights are earlier redeemed or exchanged.
A copy of the stockholder rights plan will be contained in a Form 8-K to be filed with the Securities and Exchange Commission (the "SEC").
Paul Hastings LLP is acting as legal counsel to the Company and Houlihan Lokey, Inc. is acting as financial advisor to the Company.

Offerings

Barnes & Noble Education Adopts Short-Term Stockholder Rights Plan; The Rights Will Be Exercisable Only If A Person Or Group Acquires 10% Or More Of The Co's Outstanding Common Stock, Each Right Will Entitle Stockholders To Buy One One-Thousandth Of A Share Of A New Series Of Junior Participating Preferred Stock At An Exercise Price Of $5.00.

Events

MSOS

From Benzinga's Cannabis Capital Conference: Glass House Group CEO, Kyle Kazan Says The Co's Purpose Is To Get Low Cost Cannabis To Consumers

Goldman Sachs analyst Jerry Revich maintains Atmus Filtration Techs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATMU#NYSE">ATMU</a>) with a Buy and raises the price target from $30 to $34.

ATMU

Goldman Sachs Maintains Buy on Atmus Filtration Techs, Raises Price Target to $34

Goldman Sachs analyst Jerry Revich maintains Allison Transmission (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALSN#NYSE">ALSN</a>) with a Sell and raises the price target from $55 to $63.

ALSN

Goldman Sachs Maintains Sell on Allison Transmission, Raises Price Target to $63

Highest Performances Holdings shares are trading higher after the company signed a share purchase agreement with GEM Global Yield for an investment of up to $500 million.

<ul>
<li>TSLA</li>
<li>TSM</li>
<li>DJT</li>
<li>NVDA</li>
<li>AAPL</li>
<li>GLD</li>
<li>NFLX</li>
<li>CORN</li>
<li>UNH</li>
<li>QQQ</li>
</ul>
Data from <a href="https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment">https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment</a>
&nbsp;

AAPL

CORN

NFLX

NVDA

TSLA

Top 10 Trending Stocks On WallStreetBets As Of April 16, 2024 (Via Swaggy Stocks)

TOON

Kartoon Studios Says Integrated AI Toolkit Developed On NVIDIA Omniverse Set To Revolutionize Animation Production And Distribution For The Company; The AI Initiative Aims To Save 75% Of Current Animation Production Costs While Creating Dramatic Speed-To-Market Efficiencies

Joby Aviation, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) shares are&nbsp;<a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">trading lower in the premarket session on Tuesday.</a>
The company is reportedly envisioning a futuristic commute &#8211; flying above traffic from downtown Manhattan to JFK Airport in under seven minutes, rivaling&nbsp;Uber Technologies, Inc.&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) cost.
With $400 million support from&nbsp;Toyota Motor Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>) and $60 million from&nbsp;Delta Air Lines, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>), Joby aims to lead in launching air taxis, or eVTOLs, to market, Yahoo Finance&nbsp;<a target="_blank" href="https://finance.yahoo.com/news/jetsons-like-travel-in-air-taxis-is-as-close-as-weve-seen-jobys-chief-product-officer-says-195438697.html" rel="noreferrer noopener">reported</a>.
&#8220;This is as close as we&#8217;ve seen, I think, in terms of the technology coming together to make something that you could use on a daily basis,&#8221; said Eric Allison, Joby&#8217;s chief product officer, Yahoo Finance added.
A Federal Aviation Administration spokesperson informed Yahoo Finance that while 2025 might see initial flight launches, 2028 appears more realistic for a competitive, scaled air taxi market in at least one location, the report read.
According to Wall Street research firm Jefferies, certification is the primary factor for retail investors interested in this sector to monitor closely.
Joby anticipates that their aircraft technology will aid in the regulatory process, Yahoo Finance stated.&nbsp;
The FAA&#8217;s certification demands compliance with safety standards and operational proficiency under diverse conditions.
Joby&#8217;s eVTOL boasts a range of up to 100 miles per charge, enabling two round trips between JFK and a downtown NYC heliport before needing a recharge. They anticipate recharging to coincide with passenger boarding and deplaning times.
Uber reports the average Manhattan to JFK trip costs $135 for Uber Black and $87 for regular Uber.&nbsp;
Jefferies predicts Joby&#8217;s initial ride could be around $200, Yahoo Finance added.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, JOBY stock has gained over 17% in the past year. Investors can gain exposure to the stock via&nbsp;ALPS Clean Energy ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACES#NYSE">ACES</a>) and&nbsp;First Trust NASDAQ Clean Edge Green Energy Index Fund&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QCLN#NASDAQ">QCLN</a>).
Read Next:&nbsp;<a target="_blank" href="https://www.benzinga.com/news/24/04/38024854/flying-cars-are-here-but-it-may-take-some-time-before-they-land" rel="noreferrer noopener">Flying Cars Are Here, But It May Take Some Time Before They Land</a>
Price Action: JOBY shares are trading lower by 1.09% to $4.62 premarket on the last check Tuesday. 
Dimitris Vetsikas from Pixabay

Equities

Media

General

ACES

JOBY

First Trust NASDAQ Clean Edge Green Energy Index Fund

QCLN

UBER

Joby Aviation May Launch Flying Taxis By 2025 - What's Going On?

Biotech

MYGN

New Myriad Genetics Published Study Demonstrating PPV For 22122.2 Microdeletion Screening Using Prequel Prenatal Screen

Petros Pharmaceuticals, Inc. ("Petros," or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTPI#NASDAQ">PTPI</a>), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development programs, announces it has received positive feedback from the U.S. Food and Drug Administration (the "FDA," or the "Agency") following the FDA's informal review of Petros' technology component for self-selection as the Company endeavors to achieve OTC status for STENDRA. The Agency acknowledged that the technology addressed some of its concerns regarding the PDE5 inhibitor class in that context, particularly with regard to nitrate-using patients.
Fady Boctor, Petros' President and Chief Commercial Officer, commented, "We view this meeting with the FDA as a significant step in our efforts to move STENDRA to OTC status, a move that would be the first among erectile dysfunction drug manufacturers. We found the FDA's feedback following our recent meeting to be encouraging, and we will incorporate it as we continue to move forward. We are grateful for the input from our internal advisory committee and subject matter experts and are confident that the incorporation of assistive technology has the potential to improve our process, resulting in better outcomes in our studies. We continue to believe OTC STENDRA presents a unique opportunity to treat a significant unmet medical need and look forward to further guidance from the Agency as we continue our development efforts."
During the recent Type C meeting between Petros and the FDA, the Agency also aligned with the Company in terms of its 2H 2024 submission and review of its pivotal two-arm Self-Selection study, which is currently underway. In addition, the Company received guidance from the FDA on its next technology-centered study, the Application Comprehension Study, which will be subsequently announced following additional steps being completed.
About the OTC Pathway
The process of switching a prescription medication to over the counter (OTC) first involves the design of a Drug Facts Label (DFL) that is well understood by potential consumers. Then data must show that consumers can make an appropriate decision to use or not to use the product based only upon the information on the DFL and their personal medical history. Then consumers must demonstrate that they can properly use the product based upon the information on the DFL. To accomplish these things, the FDA ordinarily requires a consumer tested OTC DFL. This testing includes conduct of iterative Label Comprehension Studies (LCS) in the general population, Self-Selection Studies (SSS) in a population interested in using the product and in specific populations who may be harmed if they use the product, and usually one Actual Use Trial (AUT) demonstrating safe and appropriate use by consumers in a simulated OTC setting.
The regulations that FDA is currently finalizing introduced Additional Conditions for Nonprescription Use (ACNU) criteria that enable correct self-selection by consumers and may expand OTC access to medications that formerly could only be available by prescription. An ACNU may be an innovative computerized tool, or the additional conditions may use other approaches that support the switch process.

PTPI

Petros Pharmaceuticals Receives Response From FDA Following Recent Demonstration Of Technology Component In Pursuit Of OTC Status For STENDRA

Oppenheimer analyst Ken Wong maintains Skillsoft (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKIL#NYSE">SKIL</a>) from Perform to Perform.

SKIL

Oppenheimer Maintains Perform on Skillsoftto Perform

<ul>
<li>Completion of partially built structures will increase total operational infrastructure at Denton data center to 197 MW, total Company-owned infrastructure to 817 MW</li>
<li>Completion expected by end of second quarter 2024</li>
<li>Expansion highlights strategic advantage of owning and controlling infrastructure and access to power</li>
</ul>
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.corescientific.com%2F&amp;esheet=53933055&amp;newsitemid=20240416234757&amp;lan=en-US&amp;anchor=Core+Scientific%2C+Inc.&amp;index=1&amp;md5=67b29bef2b754b3e70095f6260b79f4f">Core Scientific, Inc.</a> (NASDAQ:<a href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) ("Core Scientific" or "the Company"), a leader in bitcoin mining and application-specific digital infrastructure for emerging high-value compute,today announced the start of a project to complete a 72-megawatt expansion of the Company's Denton, Texas data center.
This press release features multimedia. View the full release here: <a href="https://www.businesswire.com/news/home/20240416234757/en/">https://www.businesswire.com/news/home/20240416234757/en/</a>
"Owning and controlling all of our infrastructure with access to ready power gives us the strategic optionality to expand our mining capacity, deploy upgrades to our proprietary mining technology stack, reallocate miners to optimize for efficiency and even flex to alternative forms of compute when such opportunities arise," said Adam Sullivan, Core Scientific's Chief Executive Officer. "By expanding our capacity while focusing on fleet efficiency and hash rate productivity, we believe we will remain positioned for success in the post-halving environment."
In addition to its 745-megawatts of operational infrastructure, Core Scientific owns 372 megawatts of partially built infrastructure at its two Texas data centers. The start of the Denton data center project represents the beginning of a multi-year program to complete the partially built infrastructure and expand the Company's capacity by 372-megawatts. The goal of this expansion program is to deliver more than 20 additional exahash of mining hash rate at an average incremental cost of approximately $200,000 per megawatt, or less than half the cost of new construction or asset acquisition.
Core Scientific's Denton, Texas data center currently operates 125 megawatts of bitcoin mining with total contracted power of approximately 300 megawatts. The Company's Pecos, Texas data center currently operates 71 megawatts of bitcoin mining across two sites with total contracted power of 250 megawatts.
Mr. Sullivan continued, "The exceptional performance of our data center operations team recently enabled us to deliver 16 megawatts of capacity to our high-performance computing customer in Austin, Texas more than 30 days ahead of schedule. This achievement underscores our team's ability to expand our infrastructure successfully and highlights the emerging growth opportunity in hosting alternative forms of compute."
Core Scientific data centers representing more than 500 megawatts of operational bitcoin mining infrastructure are qualified to host alternative forms of compute, based on the Company's flexible facility designs, their proximity to major metropolitan areas and access to high bandwidth fiber telecommunications infrastructure. The Company believes that the cost to convert some of its bitcoin mining infrastructure to alternative compute hosting is lower than for new construction and its completion time could be as much as 50% faster, delivering strong financial benefits to high-performance computing hosting clients.

Core Scientific, Inc. - Class A Common Stock

CORZ

Core Scientific To Expand Its Denton, Texas Bitcoin Mining Data Center By 72 Megawatts

Human Pilot Study #2 (GLP-1-H24-2) Approved
KELOWNA, BC / ACCESSWIRE / April 16, 2024 / Lexaria Bioscience Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEXX#NASDAQ">LEXX</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEXXW#NASDAQ">LEXXW</a>) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces approval has been received from an independent third-party ethics review board, for human pilot study #2 (the "Study"), investigating GLP-1 drugs and DehydraTECH.
Subject recruitment will begin immediately and the Company will announce as soon as the first dosing has begun, expected within 30 days or less. The Company anticipates completing the Study this summer.
The Study will be performed in up to 9 healthy volunteers and will study a single 7 mg dose of Rybelsus&#xAE; (semaglutide) against two different, concentration-matched 7 mg DehydraTECH-enabled semaglutide formulations from crushed Rybelsus&#xAE;.
One DehydraTECH Study arm will use a Rybelsus&#xAE; composition processed with DehydraTECH that is compliant with the U.S. Food and Drug Administration's Inactive Ingredient Database ("FDA IID"), delivered within swallowed capsules. This arm will be otherwise similar to the first DehydraTECH GLP-1 human pilot study conducted that <a href="https://pr.report/6Y3dNBFn">evidenced higher delivery of semaglutide into blood with superior blood glucose control and better tolerability</a> than was achieved with Rybelsus&#xAE;.
The second DehydraTECH Study arm will investigate an oral dissolvable tablet formulation, also compliant with the FDA IID, with DehydraTECH powered semaglutide from Ryblesus&#xAE;. This will be the first study designed to investigate whether DehydraTECH-enhanced semaglutide can effectively absorb into the sublingual/buccal tissues of the mouth and throat with fewer side effects than from swallowed administration, and with some effective level of blood absorption.
Tolerability, blood absorption levels (pharmacokinetics or "PK"), and blood sugar control will all be evaluated. The DehydraTECH compositions for this study will be compound-formulated using commercially available Rybelsus&#xAE; tablets as the semaglutide input material.
"I am excited about this Study; the Lexaria scientific team believes that a dissolvable oral tablet that delivers an effective fraction of semaglutide along with reduced side effects could potentially offer valuable benefits to the pharmaceutical industry that might lead to a higher likelihood of favorable strategic partnering with leading industry players in GLP-1," said Chris Bunka, CEO of Lexaria. "Most GLP-1 drugs sold today are administered by painful and expensive injection devices. More effective and tolerable oral delivery of GLP-1 drugs could be extremely valuable to patients and to industry."

LEXX

LEXXW

Lexaria Receives Ethics Review Board Approval To Begin New GLP-1 Study, Investigating GLP-1 Drugs And DehydraTECH

-

-

-

-

-

-

-

25% Off Benzinga's Most Powerful Trading Tools

-

-

-

-

-

-

-

Terns Pharma Stock (NASDAQ:TERN), Trade Ideas